Real Time <i>RT-PCR</i> detection of <i>TUSC2</i> gene expression in patients receiving DC-<i>TUSC2</i>.

1<p>Specimens not available.</p

Consort style flowchart of participants through the study.

<p>Consort style flowchart of participants through the study.</p

DC-<i>TUSC2</i> metabolic tumor response in a metastatic lung cancer patient.

<p>The patient is a 54 year old female with a large cell neuroendocrine carcinoma. She had received six prior chemotherapy regimens. Prior to entry in the protocol, two hepatic metastases were progressing on gemcitabine. The patient also had a metastasis in the head of the pancreas and a peripancreatic lymph node (arrows). A. Pretreatment PET scan. The dose of Fluorodeoxyglucose(18F) was 8.8mCi B. Post-treatment PET scan performed 20 days following the fourth dose of DC-<i>TUSC2</i>. The dose of Fluorodeoxyglucose(18F) was 9.0mCi. All scans were performed within a 60 to 90 minute window after injection.</p

Baseline Characteristics of Patients.

<p>Abbreviations: ECOG, Eastern Cooperative Oncology Group; NOS, not otherwise specified.</p